Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity
- PMID: 28445146
- PMCID: PMC5542301
- DOI: 10.18632/oncotarget.16944
Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity
Abstract
Doxorubicin (Dox) is a cytotoxic drug widely incorporated in various chemotherapy protocols. Severe side effects such as cardiotoxicity, however, limit Dox application. Mechanisms by which Dox promotes cardiac damage and cardiomyocyte cell death have been investigated extensively, but a definitive picture has yet to emerge. Autophagy, regarded generally as a protective mechanism that maintains cell viability by recycling unwanted and damaged cellular constituents, is nevertheless subject to dysregulation having detrimental effects for the cell. Autophagic cell death has been described, and has been proposed to contribute to Dox-cardiotoxicity. Additionally, mitophagy, autophagic removal of damaged mitochondria, is affected by Dox in a manner contributing to toxicity. Here we will review Dox-induced cardiotoxicity and cell death in the broad context of the autophagy and mitophagy processes.
Keywords: anthracyclines; heart failure; impaired autophagy and mitophagy; lysosomal dysfunction; oncocardiology.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures




Similar articles
-
Autophagic dysregulation in doxorubicin cardiomyopathy.J Mol Cell Cardiol. 2017 Mar;104:1-8. doi: 10.1016/j.yjmcc.2017.01.007. Epub 2017 Jan 17. J Mol Cell Cardiol. 2017. PMID: 28108310 Review.
-
Insulin-like growth factor II receptor-α is a novel stress-inducible contributor to cardiac damage underpinning doxorubicin-induced oxidative stress and perturbed mitochondrial autophagy.Am J Physiol Cell Physiol. 2019 Aug 1;317(2):C235-C243. doi: 10.1152/ajpcell.00079.2019. Epub 2019 May 22. Am J Physiol Cell Physiol. 2019. PMID: 31116582
-
Methionine is an essential amino acid in doxorubicin-induced cardiotoxicity through modulating mitophagy.Free Radic Biol Med. 2025 May;232:28-39. doi: 10.1016/j.freeradbiomed.2025.02.044. Epub 2025 Mar 1. Free Radic Biol Med. 2025. PMID: 40032033
-
Mitophagy inhibitor liensinine suppresses doxorubicin-induced cardiotoxicity through inhibition of Drp1-mediated maladaptive mitochondrial fission.Pharmacol Res. 2020 Jul;157:104846. doi: 10.1016/j.phrs.2020.104846. Epub 2020 Apr 25. Pharmacol Res. 2020. PMID: 32339784
-
Mitochondrial Sirtuins and Doxorubicin-induced Cardiotoxicity.Cardiovasc Toxicol. 2021 Mar;21(3):179-191. doi: 10.1007/s12012-020-09626-x. Epub 2021 Jan 12. Cardiovasc Toxicol. 2021. PMID: 33438065 Review.
Cited by
-
Implications of Breast Cancer Chemotherapy-Induced Inflammation on the Gut, Liver, and Central Nervous System.Biomedicines. 2021 Feb 13;9(2):189. doi: 10.3390/biomedicines9020189. Biomedicines. 2021. PMID: 33668580 Free PMC article. Review.
-
The Protective Effect of Flavonoids in the Diet on Autophagy-Related Cardiac Impairment.Nutrients. 2024 Jul 10;16(14):2207. doi: 10.3390/nu16142207. Nutrients. 2024. PMID: 39064651 Free PMC article. Review.
-
Ultrasound-targeted microbubble destruction (UTMD)-mediated miR-150-5p attenuates oxygen and glucose deprivation-induced cardiomyocyte injury by inhibiting TTC5 expression.Mol Biol Rep. 2022 Jul;49(7):6041-6052. doi: 10.1007/s11033-022-07392-3. Epub 2022 Mar 31. Mol Biol Rep. 2022. PMID: 35357625
-
Propofol protects cardiomyocytes from doxorubicin-induced toxic injury by activating the nuclear factor erythroid 2-related factor 2/glutathione peroxidase 4 signaling pathways.Bioengineered. 2022 Apr;13(4):9145-9155. doi: 10.1080/21655979.2022.2036895. Bioengineered. 2022. PMID: 35363601 Free PMC article.
-
The role of autophagy in death of cardiomyocytes.J Mol Cell Cardiol. 2022 Apr;165:1-8. doi: 10.1016/j.yjmcc.2021.12.006. Epub 2021 Dec 14. J Mol Cell Cardiol. 2022. PMID: 34919896 Free PMC article. Review.
References
-
- Lipshultz SE, Miller TL, Lipsitz SR, Neuberg DS, Dahlberg SE, Colan SD, Silverman LB, Henkel JM, Franco VI, Cushman LL, Asselin BL, Clavell LA, Athale U, et al. Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes. Pediatrics. 2012;130:1003–11. doi: 10.1542/peds.2012-0727. - DOI - PMC - PubMed
-
- Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11:950–61. doi: 10.1016/s1470-2045(10)70204-7. - DOI - PMC - PubMed
-
- Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, Colan SD, Neuberg DS, Dahlberg SE, Henkel JM, Asselin BL, Athale UH, Clavell LA, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012;30:1042–9. doi: 10.1200/jco.2010.30.3404. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical